Results 101 to 110 of about 10,664 (186)

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome [PDF]

, 2017
OBJECTIVE: To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Blood samples were
Gattorno, M, Obici, L, Cattalini, M, Letzkus, M, Abrams, K, Nirmala, N, Torene, R, Starck-Schwertz, S, Caorsi, R, Tormey, V, Hartmann, N, Lachmann, H   +11 more
core  

Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy

, 2019
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic diseases and malignancies. The interleukin family has been critically associated with progression of atherosclerosis, insulin resistance, and various ...
Kondapaneni, Meera, Dhorepatil, Aneesh, Lavie, Carl J., Ghosh, Raktim K., Ball, Somedeb   +4 more
core   +1 more source

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson, Sophie L. Allen, Jonathan I. Quinlan, Amritpal Dhaliwal, Michael Macleod, Joshua Price, Jon Hazeldine, Michael S. Sagmeister, Caitlin Ditchfield, Kirsty C. McGee, Felicity R. Williams, Ahmed M. Elsharkawy, Matthew J. Armstrong, Carolyn A. Greig, Janet M. Lord, Leigh Breen, Simon W. Jones   +16 more
wiley   +1 more source

Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance

, 2016
BackgroundEvidence suggests that interleukin (IL)-1β is important in the pathogenesis of atherosclerosis and its complications and that inhibiting IL-1β may favorably affect vascular disease progression.ObjectivesThe goal of this study was to evaluate ...
McLaughlin, Mary Ann, Tardif, J. C., Tardif, Jean-Claude, Zhang, Yiming, Mani, Venkatesh, Basson, C. T., Gingras, M. A., L'Allier, P. L., Zhang, Y., Fayad, Zahi A., Alie, Nadia, Robson, Matthew D., Birks, Jacqueline, Svensson, E. C., Gingras, Marc-Alexandre, Basson, Craig T., Yates, Denise, Schecter, Alison D., Alie, N., Svensson, Eric C., Gingras, M. A, L'Allier, Philippe L., Yates, D., Biasiolli, Luca, McLaughlin, M. A., Fayad, Z. A., Birks, Jacqueline S., Schecter, A. D., Mani, V., Choudhury, Robin P.   +29 more
core   +1 more source

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B‐Cell‐Specific Somatic MYD88 Mutation

Allergy, EarlyView.
Yuyi Zhou, Yoko Ueki, Naoya Iwata, Hiroshi Oue, Kentaro Kato, Mengyan Li, Kazushi Izawa, Tomoyasu Jo, Seishi Ogawa, Kenji Kabashima, Naotomo Kambe   +10 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Inflammation, Immunity, and Cardiovascular Diseases

Med Research, Volume 2, Issue 2, Page 343-370, June 2026.
Cardiovascular stress signals (e.g., hemodynamic shear, oxidized lipids, and ischemia) act on endothelial and immune cells to activate and amplify inflammation through NF‐κB, the NLRP3 inflammasome, and JAK/STAT signaling, inducing proinflammatory cytokines/chemokines (IL‐6, IL‐1β, TNF‐α, and CCL2) and self‐amplifying circuits; clinically, inflammatory
Dezhi Guo, Yan Liao, Rui Zhao, Zhaoyu Li, Kaikai Wang, Haoling Zhang, Pingxin Sun, Yadong Guo, Wangzheqi Zhang   +8 more
wiley   +1 more source

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement.
Lingzhi Qiu, Le Ma, Yifan Xie, Jing Jin, Yuting Pan, Shumin Li, Zhidan Fan, Haiguo Yu   +7 more
doaj   +1 more source

Pharmacokinetic and Pharmacodynamics of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis

, 2016
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in pediatric patients with systemic juvenile idiopathic arthritis are presented. Blood samples were obtained from 4 phase II/III clinical studies in patients
Abrams, Ken, Floch, David, Van, Linh, Jiang, Xuemin, Klein, Ulf, Sunkara, Gangadhar   +5 more
core   +1 more source

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome

, 2016
OBJECTIVE: To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS: Blood samples
Nanguneri Nirmala, Sandrine Starck-Schwertz, Meini, Antonella, Starck Schwertz, Sandrine, Rebecca Torene, Abrams, Ken, Marco Cattalini, Marco Gattorno, Ken Abrams, Starck-Schwertz, Sandrine, Martin Letzkus, Caorsi, Roberta, Gattorno, Marco, Helen Lachmann, Lachmann, Helen, Letzkus, Martin, Obici, Laura, Tormey, Vincent, Laura Obici, Caorsi, R., Vincent Tormey, Nicole Hartmann, Hartmann, Nicole, CATTALINI, Marco, Torene, Rebecca, Nirmala, Nanguneri, Roberta Caorsi   +26 more
core   +1 more source